Combination of the deacetylase inhibitor panobinostat and the mul-ti-kinase inhibitor sorafenib for the treatment of metastatic hepatocellu-lar carcinoma - Review of the underlying molecular mechanisms and first case report

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 158-165

  Gahr, Susanne ^a,b   Wissniowski, Till ^a,c   Zopf, Steffen ^a   Strobel, Deike ^a   Pustowka, Anette ^d   Ocker, Matthias ^a,e  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Deacetylase inhibitor; Hepatocellular carcinoma; Panobinostat; Sorafenib

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PANOBINOSTAT; SORAFENIB;

AGED; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; APPETITE; BACK MUSCLE; BLOOD EXAMINATION; BONE METASTASIS; CANCER STAGING; CASE REPORT; CONTRAST ENHANCEMENT; DIARRHEA; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHROCYTE COUNT; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOCRIT; HUMAN; HYPOCALCEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER INJURY; LYMPHOCYTOPENIA; MALE; METASTASIS; MONOCYTOSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTHROMBIN TIME; REVIEW; SIDE EFFECT; SOFT TISSUE METASTASIS; THYROID GLAND; VERTEBRA BODY; VERTEBRAL CANAL STENOSIS; WEIGHT REDUCTION;

EID: 84868198853     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.4211     Document Type: Review

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Okamoto K, Neureiter D, Ocker M. Biomarkers for novel targeted therapies of hepatocellular carcinoma. Histol Histopathol. 2009; 24: 493-502.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
4. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology. 2008; 48: 137-45.
5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132: 2557-76.
6. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008; 48: 1312-27.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-90.
8. Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer. 2009; 100: 19-23.
9. Carr BI, Carroll S, Muszbek N, Gondek K. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2010; 25: 1739-46.
10. Schneider-Stock R, Ocker M. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs. 2007; 10: 557-61.
11. Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res. 2011; 67: 175-95.
12. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009; 27: 5459-68.
13. Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, et al. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 2011 Aug;459(2):129-39.
14. Gahr S, Peter G, Wissniowski TT, Hahn EG, Herold C, Ocker M. The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncol Rep. 2008; 20: 1249-56.
15. Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, et al. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol. 2005; 131: 385-94.
16. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, et al. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol. 2002; 36: 233-40.
17. Di Fazio P, Schneider-Stock R, Neureiter D, Okamoto K, Wissniowski T, Gahr S, et al. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol. 2010; 32: 285-300.
18. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009; 5: 601-12.
19. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009; 280: 233-41.
20. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol. 2007; 39: 1367-74.
21. Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB, Michael MZ. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog. 2012.
22. Shin S, Lee EM, Cha HJ, Bae S, Jung JH, Lee SM, et al. MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. Int J Oncol. 2009; 35: 1343-52.
23. Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, et al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med. 2009; 24: 45-50.
24. Ocker M. Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem. 2010; 1: 55-61.
25. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol. 2009; 41: 185-98.
26. Di Fazio P, Ocker M, Montalbano R. New Drugs, Old Fashioned Ways: Er Stress Induced Cell Death. Curr Pharm Biotechnol. 2011.
27. Ocker M, Höpfner M. Apoptosis-modulating drugs for improved cancer therapy. Eur Surg Res. 2012; doi:10.1159/00036875.
28. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006; 12: 634-42.
29. Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 2012.
30. LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, et al. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011; 71: 3635-48.
31. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009; 280: 145-53.
32. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66: 11851-8.
33. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006; 407: 597-612.
34. Park MA, Reinehr R, Haussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, et al. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther. 2010; 9: 2220-31.
35. Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Haussinger D, et al. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res. 2010; 70: 6313-24.
36. Ullen A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L, et al. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol. 2010; 37: 15-20.
37. Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy. 2011.
38. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, et al. Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012.
39. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist. 2009; 14: 717-25.
40. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100: 698-711.
41. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099-109.
42. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, et al. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res. 2008; 14: 5385-99.
43. Walker T, Mitchell C, Park MA, Yacoub A, Graf M, Rahmani M, et al. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol. 2009; 76: 342-55.
44. Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, et al. Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells. Cancer Res. 2011; 71: 4955-67.
45. Bitzer M, Horger M, Ganten T, Ebert MP, Siveke J, Woerns MA, et al. Clinical Update of the SHELTER Study: A Phase I/II Trial of HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC). Ann Oncol. 2011; 22: v76-v.